|
|
SPOT ON
|
|
Passing bell for Rosiglitazone (AVANDIA)?
|
|
|
NEW ON THE MARKET
|
|
COPD: phosphodiesterase-4 inhibitor roflumilast (DAXAS)
Me too: alpha blocker silodosin (UROREC) for prostatic hyperplasia
|
|
|
THERAPY FROM A CRITICAL VIEWPOINT
|
|
Bevacizumab (AVASTIN) without benefit in breast cancer
|
|
|
a-t READER'S QUESTIONS AND COMMENTS
|
|
Novo Nordisk: foregoing profit for the benefit of patients?
|
|
|
IN BRIEF
|
|
"Flu" vaccines for 2010/11
Alteplase (ACTILYSE) for acute ischemic stroke
Celecoxib (CELEBREX) better than diclofenac (VOLTAREN, generics) plus omeprazole (ANTRA, generics)?
Tranexamic acid (CYKLOKAPRON) use for severe trauma
|
|
|
SIDE EFFECTS
|
|
Prescription required for topical ketoprofen (e.g. ADVEL pain relieving gel)
Serious liver injury due to leflunomide (ARAVA)
Modafinil (VIGIL) soon restricted to narcolepsy only?
|
|
|
CURRENT ADR NETWORK REPORT
|
|
Liver injury due to dronedarone (MULTAQ)?
|
|
|
DOCUMENTATION
|
|
Rise and fall of the glitazone rosiglitazone (AVANDIA)
|
|